View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 29, 2022

BMS receives US FDA approval for Camzyos to treat cardiomyopathy

The approval is based on findings from Phase III EXPLORER-HCM clinical trial that enrolled 251 adults with obstructive HCM.

Bristol Myers Squibb (BMS) has received US Food and Drug Administration (FDA) approval for Camzyos (mavacamten, 2.5mg, 5mg, 10mg, 15mg capsules) to treat adult patients with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (HCM).

The treatment is intended at enhancing functional capacity and symptoms in such patients. 

Camzyos is an allosteric and reversible inhibitor of cardiac myosin.

Hindering myosin using Camzyos lowers dynamic left ventricular outflow tract (LVOT) obstruction and enhances cardiac filling pressures in patients with HCM.

The company noted that Camzyos is the first allosteric and reversible inhibitor selective for cardiac myosin that acts on the obstructive HCM’s underlying pathophysiology, to obtain FDA approval.

The full US Prescribing Information for the therapy comprises a boxed warning for heart failure risk. 

This FDA approval is based on findings from the double-blind, randomised, placebo-controlled, parallel-group Phase III EXPLORER-HCM clinical trial which enrolled 251 adults with symptomatic, obstructive HCM.

The trial’s composite primary endpoint was the proportion of subjects attaining either improvement of mixed venous oxygen tension (pVO2) by ≥1.5 mL/kg/min plus improvement in NYHA class by a minimum of one or improvement of pVO2 by ≥3.0 mL/kg/min without worsening in NYHA class at week 30.

Trial data showed that 37% of subjects who received Camzyos met the composite primary endpoint versus 17% in the placebo arm. 

Furthermore, subjects in the Camzyos arm had enhanced improvement across all secondary endpoints versus placebo at week 30.

Bristol Myers Squibb Global Drug Development executive vice-president and chief medical officer Samit Hirawat said: “This approval builds on decades of cardiovascular leadership and reflects our steadfast commitment to people impacted by cardiovascular disease.

“We are proud to bring this first-of-its-kind medicine to patients, which may help to address an unmet need in the US in the symptomatic NYHA class II-III obstructive HCM treatment landscape.”

In March this year, the US FDA approved BMS’ Opdivo (nivolumab) plus platinum-doublet chemotherapy to treat adults with resectable non-small cell lung cancer in the neoadjuvant setting.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU